Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State

Article Abstract:

The prevalence of drug-resistant and non-subtype B strains of HIV in perinatally infected infants diagnosed in New York State in 2001 and 2002 is determined and the association between perinatal antiretroviral (ARV) exposure and drug resistance in this population is investigated. The results have shown the value of resistance testing for all HIV-infected infants upon diagnosis and the need to consider subtype diversity in diagnostic and treatment strategies.

Diagnosis, HIV infection, Drug therapy, HIV infections, Drug resistance

---

Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients

Article Abstract:

A study was conducted to establish that GS-9137 is a potent low nano-molar strand transfer inhibitor of HIV-1 integrase, evaluating its antiviral activity, tolerability, pharmacokinetics, and pharmacodynamics in a randomized, double-blind, placebo-controlled monotherapy study in 40 HIV-1-infected patients. The results showed that GS-9137 demonstrated substantial short-term antiviral activity and was well tolerated as monotherapy, warranting further study.

Health aspects, HIV patients, Pharmacokinetics, Clinical report, Integrase inhibitors, Viral drug resistance

---

Similar abstracts:

• Abstracts: Tracking the prevalence of transmitted antiretroviral drug- resistant HIV- 1: A decade experience. Bioengineering lactic acid bacteria to secrete the HIV-1 virucide cyanovirin
• Abstracts: Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: The Swiss HIV cohort study. part 2
• Abstracts: Gastrointestinal tract. The management of animal and human bite wounds
• Abstracts: Evaluation of HIV-1 p24 antigenemia and level of CD8(super +)CD38(super +) T cells as surrogate markers of HIV- 1 RNA viral load in HIV-1-infected patients in Dakar, Senegal. part 2

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.